Satoh Chikako, Ogata Kiyoyuki
Third Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Leuk Res. 2006 Apr;30(4):491-5. doi: 10.1016/j.leukres.2005.08.017. Epub 2005 Sep 22.
The transformation site in acute myeloid leukemia (AML) has been proposed to be pluripotent hematopoietic stem cells (PHSCs), and the lymphoid development of leukemic PHSCs may be suppressed by leukemogenic events. Recent data from multiple laboratories have contradicted the current hierarchical model of hematopoiesis and indicated the presence of myeloid HSCs with minimal lymphopoietic potential (MyHSCs) in mice. Based on these findings and re-evaluating the published data on AML stem cells, we hypothesize that MyHSCs may be the transformation site in AML. If so, therapy targeting leukemic MyHSCs but sparing PHSCs is worth investigating.
急性髓系白血病（AML）的转化位点被认为是多能造血干细胞（PHSCs），白血病性PHSCs的淋巴样发育可能会被致白血病事件所抑制。多个实验室的最新数据与当前的造血层次模型相矛盾，并表明小鼠中存在具有最小淋巴细胞生成潜能的髓系造血干细胞（MyHSCs）。基于这些发现并重新评估已发表的关于AML干细胞的数据，我们推测MyHSCs可能是AML的转化位点。如果是这样，靶向白血病性MyHSCs但不损伤PHSCs的治疗方法值得研究。
